When and where: A study on gastric cancer recurrence after neoadjuvant/perioperative chemotherapy

Table 4 Univariable overall survival

Variable	Number of patients	Number of events	5 years OS (95%CI)	Median OS in months (95%CI)	P value (log-rank test)
Overall patients	86	45	57.1 (45.5-67.1)	69.6 (44.2-115.1)
BMI
Underweight or normal (< 25)	32	24	42.9 (25.5-59.1)	41.6 (20.7-78.3)	0.008
Overweight or obesity (≥ 25.0)	53	21	64.8 (49.4-76.6)	115.1 (59.9-NE)
Unknown	1	0
cT
T2	3	2
T3	45	18	63.4 (47.2-75.8)	NR	0.045
T4	38	25	48.0 (30.5-63.5)	59.9 (39.1-89.4)
Lauren histotype
Diffuse	34	24	37.8 (21.3-54.3)	40.6 (21.3-69.6)	0.001
Intestinal	38	13	72.7 (54.5-84.1)	NR
Other	14	7
Unknown	2	1
Treatment
Arm A	44	21	58.7 (41.9-72.2)	78.2 (40.5-NE)	0.806
Arm B	42	24	55.0 (38.4-68.9)	65.0 (41.1-115.1)
Response (Becker + lymph nodes)
Poor responders	57	32	50.4 (36.4-62.8)	60.5 (40.5-NE)	0.034
Good responders	24	8	85.7 (61.7-95.2)	115.1 (65.0-NE)

Strata with fewer than 15 patients were excluded from the log-rank test calculation. OS: Overall survival; CI: Confidence interval; BMI: Body mass index; NE: Not estimable from statistical software; NR: Median not reached.